Pharmaceutical Firms Lie, Cheat & Steal from America’s Elderly, Orphans, Poor and Helpless
Posted by Warm Southern Breeze on Saturday, September 8, 2012
A few points for the reader to consider:
This fraud was national in scope, involving a $3 BILLION settlement, of which the North Carolina Attorney General was able to recoup $31.8M. Pfizer, Abbott, Johnson & Johnson, Forest Labs, Eli Lilly, Astrazeneca have also all plead guilty to deceptive and fraudulent marketing. It’s very likely a drop in the bucket in comparison with the greater scope.
The four most expensive Pharmacy frauds in the United States history have occurred since George W. Bush oversaw the rewriting of the Medicare Part D drug benefit in 2003. In order of their value, they are:
GlaxoSmithKline – $3 Billion, 2012
Pfizer – $2.3 Billion, 2009
Abbott Laboratories – $1.5 Billion, 2012
Eli Lilly – $1.4 Billion, 2009
The so-called “doughnut hole” in the Medicare prescription Part D drug plan was closed by President Obama. That “doughnut hole” was created under the George W. Bush administration, who caved in to lobbyists from BIG PHARMA, and allowed them to write much of that aspect of the 2003 revision of the Medicare Part D law (also known as the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), and refused to allow Medicaid the opportunity to bargain for prices with pharmaceutical firms.
Advertising is expensive. Advertising for medications on television, radio, Internet, magazines, billboards, buses, and any other place where advertising is sold, is illegal in some nations. It was once illegal in the United States, until the 1980′s when the FDA OK’d it under pressure from the Reagan administration.
IMS Health, a medical data firm, calculates that drug companies’ business in the United States alone earns more than $300 billion a year.
Last year, GSK had $20 Billion gross profits on $27 Billion in revenue. So don’t let anyone EVER fool you into believing that drug companies don’t make enough money, don’t have enough profits, or enough profit margin.
Pharmaceutical companies spent $188 Million lobbying Congress in 2009, which is more than all but a few industry sectors, and employed an army of 1,105 lobbyists, according to the nonpartisan Center for Responsive Politics. And according to the non-partisan Center for Public Integrity, from 1998-2006, the Pharmaceutical Industry spent $855 Million lobbying Congress, more than any other industry.
Expensive brand-name designer biotech drugs – which account for 15% of all pharmaceutical sales – now have 12 years of patent protection against cheaper generic competitors.
There were 44 states involved in the settlement. Here’s a partial list of states and their recoveries:
• Florida will recover $56 Million
• Alabama will recover a total of $5,909,500
• California will recover $46 M
• Massachusetts will recover $35 Million
• Michigan will recover $1.2 Million
• New York State will recover $146 Million
• Virginia will recover $8.6 Million
• Missouri will recover $32 Million
NC recoups $31.8 million from GlaxoSmithKline, AG Cooper announces
Release date: 9/6/2012
AG’s expanded Medicaid fraud unit taking on more cases than ever before
Raleigh: North Carolina has recovered $31.8 million from drug maker GlaxoSmithKline as part of the largest health care fraud settlement in U.S. history, Attorney General Roy Cooper announced today. “Wrongdoing by drug companies and health care providers wastes taxpayers’ money, deprives needy patients of care, and inflates medical costs for all of us,” said Cooper. “We’re continuing our crackdown on fraud and abuse in our health care system.”
The settlement with GlaxoSmithKline (GSK) is the latest recovery made by Cooper’s Medicaid Investigations Division, which has recouped nearly $500 million over the past decade and helped to convict hundreds of individuals on criminal charges. The division has nearly doubled in size in recent years with the addition of new attorneys, investigators, criminal information analysts and support staff, allowing it to take on 46 percent more investigations than before.
Of the $31.8 million recovered by North Carolina, nearly $3.9 million will go to North Carolina public schools. The remaining funds will go to support Medicaid efforts in the state. The funds are part of a $3 billion national settlement to resolve allegations that GSK used various illegal schemes to market and price drugs including Paxil, Wellbutrin, Advair, Lamictal, and Zofran. The national settlement includes $2 billion in civil penalties and $1 billion in criminal fines.
The settlement GSK resolves allegations that company unlawfully made false representations about drug safety and efficacy, offered kickbacks to doctors, marketed certain drugs for off-label use (uses not approved by the Food and Drug Administration), and underpaid rebates owed to taxpayer-funded programs including Medicaid. Specifically, North Carolina, other states and the federal government alleged that GSK:
- Marketed the depression drugs Paxil and Wellbutrin, the asthma drug Advair, the seizure medication Lamictal, and the nausea drug Zofran for off-label uses;
- Made false representations about the safety and efficacy of Paxil, Wellbutrin, Advair, Lamictal, Zofran, and the diabetes drug Avandia;
- Offered kickbacks, including entertainment, cash, travel, and meals, to healthcare professionals to induce them to promote and prescribe Paxil, Wellbutrin, Advair, Lamictal, Zofran, the migraine drug Imitrex, the irritable bowel syndrome drug Lotronex, the asthma drug Flovent, and the shingles and herpes drug Valtrex; and
- Submitted incorrect pricing data for various drugs, causing the company to underpay rebates owed to Medicaid and other taxpayer-funded health care programs.
As part of the settlement, GSK also agreed to plead guilty to criminal charges that it violated the federal Food, Drug, and Cosmetic Act in connection with misbranding Wellbutrin and Paxil and failing to report certain clinical data regarding Avandia to the FDA.
The national settlement is based on four whistleblower actions brought by private individuals. North Carolina’s share of the settlement was reached by Cooper’s Medicaid Investigations Division (MID) and the North Carolina Division of Medical Assistance.
The settlement with GlaxoSmithKline is one of several major Medicaid fraud settlements reached by the Attorney General’s Office with drug makers in recent months, including:
- $21.7 million recovered from McKesson Corporation for inflating prices on drugs, causing the state’s Medicaid program to pay too much for those drugs.
- $11.7 million recovered from Maxim Health Services for submitting claims for services it didn’t provide and for submitting claims without the required documentation.
- $818,490.47 recovered from Dava Pharmaceuticals, Inc. to resolve allegations that the company underpaid rebates it owed to Medicaid.
The MID investigates fraud and abuse of Medicaid benefits by hospitals, doctors, pharmaceutical companies, medical equipment companies, mental health and personal care providers, ambulance services and others. The division also investigates patient abuse and neglect in nursing homes and other facilities that receive Medicaid funds. The unit includes attorneys, investigators and State Bureau of Investigation agents who work closely with United States Attorneys, District Attorneys, and other state and federal law enforcement agencies.
“With more investigators, agents and prosecutors on the health care fraud beat, we’re working harder than ever to stop Medicaid cheaters,” Cooper said.